Cardiotonic Agents Market

Cardiotonic Agents Market (Drug Type: Digitalis Glycosides, Phosphodiesterase Inhibitors, Cardioprotectants, Sympathomimetic Agents, and Others) - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2023-2031

Global Cardiotonic Agents Market Outlook 2031

  • The global industry was valued at US$ 732.0 Mn in 2022
  • It is projected to advance at a CAGR of 21.3% from 2023 to 2031 and reach more than US$ 4.5 Bn by the end of 2031

Analysts’ Viewpoint

Rise in prevalence of cardiovascular diseases is significantly driving the cardiotonic agents industry growth. High incidence of heart diseases and the presence of well-established healthcare infrastructure across several countries are contributing to the cardiotonic agents market development. Rise in number of cardiac surgeries across the globe and development of new medications for emergency and critical care situations are augmenting market growth.

Advancements in drug development are creating lucrative cardiotonic agents market opportunities for market participants. Manufacturers in the market are engaged in R&D activities to explore new types of cardiotonic agents. Development of medications, such as sodium-glucose cotransporter 2 (SGLT2) inhibitors, which can improve heart function is fueling market statistics.

Cardiotonic Agents Market

Market Introduction

Cardiotonic agents, also known as inotropic agents, are medications that affect the heart's contractility and improve its function. These agents are commonly used in the treatment of heart failure, arrhythmias, and other cardiovascular conditions.

Digoxins are cardiotonic drugs that are used to increase the force of the heart's contractions and slow down the heart rate, thereby improving blood circulation. Digitalis glycosides have been used for decades and are still a common treatment option for heart failure, atrial fibrillation, and other cardiovascular conditions. However, their use has declined in the last few years due to the availability of newer medications with fewer side effects.

Another type of cardiotonic agent is beta-adrenergic agonists, such as dobutamine. These drugs stimulate the beta-receptors in the heart and increase the heart's contractility. Beta-adrenergic agonists are commonly utilized in the treatment of acute heart failure and shock, as they rapidly increase cardiac output and improve blood pressure. However, their use is limited due to their potential for adverse effects, such as tachycardia and arrhythmias.

Calcium sensitizers, such as levosimendan, are a newer class of cardiotonic agents that improve the heart's contractility by increasing its sensitivity to calcium. Calcium sensitizers are used in the treatment of heart failure and are particularly effective in patients with reduced ejection fraction.

Rise in Prevalence of Cardiovascular Diseases

Cardiovascular diseases (CVDs) are a major cause of morbidity and mortality worldwide, with heart failure being one of the most common cardiovascular conditions. The incidence of heart failure is expected to rise in the near future, owing to the rise in the geriatric population and the surge in the prevalence of obesity, diabetes, and high blood pressure. This has led to an increased demand for cardiotonic agents to manage the condition. Several new medications are being developed to reduce the risk of cardiovascular death.

According to a report by the American Heart Association, heart failure affects nearly 6.2 million adults in the U.S., and it is projected to increase by 46.0% by 2030. The rise in the prevalence of heart failure is driving the demand for cardiotonic agents such as digoxin and milrinone, which are commonly used to improve cardiac function in patients with heart failure.

Development of New Cardiotonic Agents with Improved Efficacy and Safety Profiles

Technological advancements in the development of cardiotonic agents are driving market progress. New drugs are being developed with improved efficacy and safety profiles. Novartis developed Entresto, a combination drug that has been shown to be effective in reducing cardiovascular death and hospitalization for heart failure.

In addition to the development of new drugs, companies are also investing in the development of advanced drug delivery systems and novel formulations. For instance, Milestone Pharmaceuticals has developed a novel drug delivery system for etripamil, a drug used to treat certain types of cardiac arrhythmias. The delivery system allows for rapid administration of etripamil and has been shown to be effective in treating patients with supraventricular tachycardia.

Other companies are exploring the use of nanotechnology in the development of novel formulations for cardiotonic agents. Nanotechnology involves the manipulation of particles on a nanoscale level and has the potential to improve the efficacy and safety of drugs.

A surge in Demand for Phosphodiesterase Inhibitors

The phosphodiesterase inhibitors drug type segment dominated the global industry in 2022. This segment is likely to maintain its dominance during the forecast period. Growth of the phosphodiesterase inhibitors drug type segment is attributable to the increase in the prevalence of heart failure and other cardiovascular diseases, as well as the rise in demand for effective and safe treatments.

Sildenafil is a phosphodiesterase inhibitor that was originally developed as a treatment for erectile dysfunction; however, later, it was found to be effective for cardiovascular diseases. Studies have shown that sildenafil can improve exercise capacity and quality of life in patients with heart failure.

Growth in the Number of Cardiac Surgical Procedures to Drive Demand for Cardiotonic Medications

The cardiac surgical procedures application segment accounted for the largest share of the global market in 2022. The increase in demand for cardiac surgeries, such as bypass surgeries, valve replacements, and heart transplants, as well as the rise in the need for medications to support and enhance the outcomes of these surgeries, are driving the segment.

Dopamine is often used during cardiac surgery to increase blood pressure and improve cardiac output. Other medications commonly used in cardiac surgical procedures include nitroglycerin, which can dilate blood vessels and improve blood flow, and heparin, which is used to prevent blood clots during surgery.

Several pharmaceutical companies have been investing in the development of new cardiotonic agents to improve the outcomes of cardiac surgical procedures.

Development of New Medications for Emergency and Critical Care Situations

In terms of the route of administration, the global market has been divided into oral and parenteral. As per the latest cardiotonic agents market trends, the parenteral route of administration segment dominated in 2022. It is anticipated to lead the global market in the next few years.

Parenteral administration refers to the delivery of medication through injection or infusion directly into the bloodstream, bypassing the gastrointestinal tract. This route of administration is often used for cardiotonic agents in emergency and critical care situations, where rapid onset and precise dosing are crucial.

Common examples of parenteral cardiotonic agents include dobutamine, which is used to improve heart function in cases of acute heart failure. Other medications administered parenterally include epinephrine, norepinephrine, and nitroglycerin.

Several pharmaceutical companies have started investing in the development of new parenteral cardiotonic agents, including Novartis and its medication LCZ696, which has shown promising results in the treatment of heart failure.

Increase in New Formulations and Delivery Methods of Drugs

According to the latest cardiotonic agents market analysis, the solution dosage form segment accounted for major share of the global industry in 2022. The solution dosage form segment is projected to lead the global market in the near future.

Cardiotonic agents can be delivered effectively using oral solutions, intravenous solutions, and others. Digoxin is given in a solution form, which is commonly used in the treatment of heart failure and certain arrhythmias. It is available in both oral and intravenous solution forms.

High Demand for Cardiotonic Drugs in Hospital Pharmacies

Based on distribution channels, the global industry has been divided into hospital pharmacies retail pharmacies, and online pharmacies. According to the latest cardiotonic agents industry research report, the hospital pharmacies distribution channel segment is expected to account for major share during the forecast period.

Hospital pharmacies are an important distribution channel for cardiotonic agents, as these medications are often administered in a hospital or clinical setting, and require specialized expertise for proper storage, handling, and administration.

Retail pharmacies are often used for the distribution of oral cardiotonic agents for outpatient use, while online pharmacies are becoming increasingly popular for the purchase and delivery of these medications.

Regional Outlook of Global Cardiotonic Agents Industry

As per the latest cardiotonic agents market forecast, North America held major share of the global landscape in 2022. It is projected to maintain its dominance during the forecast period. This can be attributed to high prevalence of cardiovascular diseases in the region, advanced healthcare infrastructure, and increase in healthcare spending.

The U.S. is the largest market for cardiotonic agents in North America, with several major pharmaceutical companies operating in the region. These companies include Pfizer Inc, Novartis, and Amgen. These companies are actively engaged in the development and commercialization of cardiotonic agents.

The cardiotonic agents market size in Asia Pacific is anticipated to increase in the near future. Rise in incidence of cardiovascular diseases and increase in demand for effective treatments are significant factors fueling cardiotonic agents market growth in the region.

The cardiotonic agents market demand is rising in Asia Pacific due to the rise in geriatric population in the region. The presence of several major pharmaceutical companies in Asia Pacific countries, such as Japan, China, and India, is fueling market expansion in the region.

Analysis of Key Players in Global Cardiotonic Agents Market

Amneal Pharmaceuticals LLC, Pfizer Inc., Hikma Pharmaceuticals PLC, Fresenius Kabi, Midas Pharma GmbH, Sanofi, Aurobindo Pharma Limited, and SimSon Pharma Limited are the major players operating in the global market. These players are engaged in mergers & acquisitions, strategic collaborations, and new product launches to strengthen their cardiotonic agents market share.

Key Developments

  • In February 2022, Roche announced positive results from a phase III clinical trial of its heart failure drug, furosemide, which is a loop diuretic that reduces fluid buildup in the body and improves cardiac function.
  • In January 2022, Merck & Co., Inc. announced positive results from a phase II clinical trial of its heart failure drug, vericiguat, which is a soluble guanylate cyclase stimulator that improves cardiac function.
  • In December 2021, Pfizer Inc. announced positive results from a phase III clinical trial of its oral thrombin inhibitor, betrixaban, for the prevention of blood clots in acutely ill medical patients.
  • In November 2021, Novartis announced positive results from a phase III clinical trial of its heart failure drug, Entresto (sacubitril/valsartan), in patients with preserved ejection fraction, which is a major form of heart failure that has been difficult to treat.
  • In May 2021, Amgen received FDA approval for its heart failure drug omecamtiv mecarbil, which is a novel cardiac myosin activator that improves cardiac contractility and is intended for patients with heart failure with reduced ejection fraction.

Key players have been profiled in the cardiotonic agents market report based on parameters such as business strategies, company overview, product portfolio, financial overview, business segments, and recent developments.

Market Snapshot

Attribute

Detail

Market Size in 2022

US$ 732.0 Mn

Forecast (Value) in 2031

More than US$ 4.5 Bn

Growth Rate (CAGR)

21.3%

Forecast Period

2023–2031

Historical Data Available for

2017–2022

Quantitative Units

US$ Mn/Bn for Value

Market Analysis

It includes segment analysis as well as regional level analysis. Moreover, qualitative analysis includes drivers, restraints, opportunities, key trends, Porter’s Five Forces analysis, value chain analysis, and key trend analysis.

Competition Landscape

  • Market share analysis by company (2022)
  • Company profiles section includes overview, product portfolio, sales footprint, key subsidiaries or distributors, strategy & recent developments, and key financials

Format

Electronic (PDF) + Excel

Segmentation

  • Drug Type
    • Digitalis Glycosides
    • Phosphodiesterase Inhibitors
    • Cardioprotectants
    • Sympathomimetic Agents
    • Others
  • Application
    • Cardiac Surgical Procedures
    • Atrial Fibrillation
    • Heart Failure
    • Pulmonary Hypertension
    • Others (Atrial Flutter, Cardiogenic Shock, etc.)
  • Route of Administration
    • Oral
    • Parenteral
  • Dosage Form
    • Tablet
    • Solution
    • Others
  • Distribution Channel
    • Hospital Pharmacies
    • Retail Pharmacies
    • Online Pharmacies

Regions Covered

  • North America
  • Europe
  • Asia-Pacific
  • Latin America
  • Middle East & Africa

Countries Covered

  • U.S.
  • Canada
  • Germany
  • U.K.
  • France
  • Italy
  • Spain
  • China
  • Japan
  • India
  • Australia & New Zealand
  • Rest of Asia Pacific
  • Brazil
  • Mexico
  • Rest of Latin America
  • GCC Countries
  • South Africa
  • Rest of Middle East & Africa

Companies Profiled

  • Amneal Pharmaceuticals LLC
  • Pfizer Inc.
  • Hikma Pharmaceuticals PLC
  • Fresenius Kabi
  • Midas Pharma GmbH
  • Sanofi
  • Aurobindo Pharma Limited
  • SimSon Pharma Limited
  • Other Players

Customization Scope

Available upon request

Pricing

Available upon request

Frequently Asked Questions

How big was the global cardiotonic agents market in 2022?

The global market was valued at US$ 732.0 Mn in 2022.

How big will it be in 2031?

It is projected to reach more than US$ 4.5 Bn by 2031.

What will be the CAGR during the forecast period?

The CAGR is anticipated to be 21.3% from 2023 to 2031.

Which application segment accounted for major share in 2022?

The cardiac surgical procedures application segment held major share in 2022.

Which region is expected to account for major share of the global industry during the forecast period?

North America is expected to account for major share during the forecast period.

Who are the prominent players in the cardiotonic agents business?

Amneal Pharmaceuticals LLC, Pfizer Inc., Hikma Pharmaceuticals PLC, Fresenius Kabi, Midas Pharma GmbH, Sanofi, Aurobindo Pharma Limited, and SimSon Pharma Limited.

1. Preface

    1.1. Market Definition and Scope

    1.2. Market Segmentation

    1.3. Key Research Objectives

    1.4. Research Highlights

2. Assumptions and Research Methodology

3. Executive Summary: Global Cardiotonic Agents Market

4. Market Overview

    4.1. Introduction

    4.2. Overview

    4.3. Market Dynamics

        4.3.1. Drivers

        4.3.2. Restraints

        4.3.3. Opportunities

    4.4. Global Cardiotonic Agents Market Analysis and Forecast, 2017–2031

5. Key Insights

    5.1. Key Industry Events

    5.2. Technological Advancements

    5.3. Value Chain Analysis

    5.4. COVID-19 Pandemic Impact on Industry (value chain and short/mid/long term impact)

6. Global Cardiotonic Agents Market Analysis and Forecast, by Drug Type

    6.1. Introduction & Definition

    6.2. Key Findings/Developments

    6.3. Market Value Forecast, by Drug Type, 2017–2031

        6.3.1. Digitalis Glycosides

        6.3.2. Phosphodiesterase Inhibitors

        6.3.3. Cardioprotectants

        6.3.4. Sympathomimetic Agents

        6.3.5. Others

    6.4. Market Attractiveness Analysis, by Drug Type

7. Global Cardiotonic Agents Market Analysis and Forecast, by Application

    7.1. Introduction & Definition

    7.2. Key Findings/Developments

    7.3. Market Value Forecast, by Application, 2017–2031

        7.3.1. Cardiac Surgical Procedures

        7.3.2. Atrial Fibrillation

        7.3.3. Heart Failure

        7.3.4. Pulmonary Hypertension

        7.3.5. Others (Atrial Flutter, Cardiogenic Shock, etc.)

    7.4. Market Attractiveness Analysis, by Application

8. Global Cardiotonic Agents Market Analysis and Forecast, by Route of Administration

    8.1. Introduction & Definition

    8.2. Key Findings/Developments

    8.3. Market Value Forecast, by Route of Administration, 2017–2031

        8.3.1. Oral

        8.3.2. Parenteral

    8.4. Market Attractiveness Analysis, by Route of Administration

9. Global Cardiotonic Agents Market Analysis and Forecast, by Dosage Form

    9.1. Introduction & Definition

    9.2. Key Findings/Developments

    9.3. Market Value Forecast, by Dosage Form, 2017–2031

        9.3.1. Tablet

        9.3.2. Solution

        9.3.3. Others

    9.4. Market Attractiveness Analysis, by Dosage Form

10. Global Cardiotonic Agents Market Analysis and Forecast, by Distribution Channel

    10.1. Introduction & Definition

    10.2. Key Findings/Developments

    10.3. Market Value Forecast, by Distribution Channel, 2017–2031

        10.3.1. Hospital Pharmacies

        10.3.2. Retail Pharmacies

        10.3.3. Online Pharmacies

    10.4. Market Attractiveness Analysis, by Distribution Channel

11. Global Cardiotonic Agents Market Analysis and Forecast, by Region

    11.1. Key Findings

    11.2. Market Value Forecast, by Region, 2017–2031

        11.2.1. North America

        11.2.2. Europe

        11.2.3. Asia Pacific

        11.2.4. Latin America

        11.2.5. Middle East & Africa

    11.3. Market Attractiveness Analysis, by Region

12. North America Cardiotonic Agents Market Analysis and Forecast

    12.1. Introduction

        12.1.1. Key Findings

    12.2. Market Value Forecast, by Drug Type, 2017–2031

        12.2.1. Digitalis Glycosides

        12.2.2. Phosphodiesterase Inhibitors

        12.2.3. Cardioprotectants

        12.2.4. Sympathomimetic Agents

        12.2.5. Others

    12.3. Market Value Forecast, by Application, 2017–2031

        12.3.1. Cardiac Surgical Procedures

        12.3.2. Atrial Fibrillation

        12.3.3. Heart Failure

        12.3.4. Pulmonary Hypertension

        12.3.5. Others (Atrial Flutter, Cardiogenic Shock, etc.)

    12.4. Market Value Forecast, by Route of Administration, 2017–2031

        12.4.1. Oral

        12.4.2. Parenteral

    12.5. Market Value Forecast, by Dosage Form, 2017–2031

        12.5.1. Tablet

        12.5.2. Solution

        12.5.3. Others

    12.6. Market Value Forecast, by Distribution Channel, 2017–2031

        12.6.1. Hospital Pharmacies

        12.6.2. Retail Pharmacies

        12.6.3. Online Pharmacies

    12.7. Market Value Forecast, by Country, 2017–2031

        12.7.1. U.S.

        12.7.2. Canada

    12.8. Market Attractiveness Analysis

        12.8.1. By Drug Type

        12.8.2. By Application

        12.8.3. By Route of Administration

        12.8.4. By Dosage Form

        12.8.5. By Distribution Channel

        12.8.6. By Country

13. Europe Cardiotonic Agents Market Analysis and Forecast

    13.1. Introduction

        13.1.1. Key Findings

    13.2. Market Value Forecast, by Drug Type, 2017–2031

        13.2.1. Digitalis Glycosides

        13.2.2. Phosphodiesterase Inhibitors

        13.2.3. Cardioprotectants

        13.2.4. Sympathomimetic Agents

        13.2.5. Others

    13.3. Market Value Forecast, by Application, 2017–2031

        13.3.1. Cardiac Surgical Procedures

        13.3.2. Atrial Fibrillation

        13.3.3. Heart Failure

        13.3.4. Pulmonary Hypertension

        13.3.5. Others (Atrial Flutter, Cardiogenic Shock, etc.)

    13.4. Market Value Forecast, by Route of Administration, 2017–2031

        13.4.1. Oral

        13.4.2. Parenteral

    13.5. Market Value Forecast, by Dosage Form, 2017–2031

        13.5.1. Tablet

        13.5.2. Solution

        13.5.3. Others

    13.6. Market Value Forecast, by Distribution Channel, 2017–2031

        13.6.1. Hospital Pharmacies

        13.6.2. Retail Pharmacies

        13.6.3. Online Pharmacies

    13.7. Market Value Forecast, by Country/Sub-region, 2017–2031

        13.7.1. Germany

        13.7.2. U.K.

        13.7.3. France

        13.7.4. Italy

        13.7.5. Spain

        13.7.6. Rest of Europe

    13.8. Market Attractiveness Analysis

        13.8.1. By Drug Type

        13.8.2. By Application

        13.8.3. By Route of Administration

        13.8.4. By Dosage Form

        13.8.5. By Distribution Channel

        13.8.6. By Country/Sub-region

14. Asia Pacific Cardiotonic Agents Market Analysis and Forecast

    14.1. Introduction

        14.1.1. Key Findings

    14.2. Market Value Forecast, by Drug Type, 2017–2031

        14.2.1. Digitalis Glycosides

        14.2.2. Phosphodiesterase Inhibitors

        14.2.3. Cardioprotectants

        14.2.4. Sympathomimetic Agents

        14.2.5. Others

    14.3. Market Value Forecast, by Application, 2017–2031

        14.3.1. Cardiac Surgical Procedures

        14.3.2. Atrial Fibrillation

        14.3.3. Heart Failure

        14.3.4. Pulmonary Hypertension

        14.3.5. Others (Atrial Flutter, Cardiogenic Shock, etc.)

    14.4. Market Value Forecast, by Route of Administration, 2017–2031

        14.4.1. Oral

        14.4.2. Parenteral

    14.5. Market Value Forecast, by Dosage Form, 2017–2031

        14.5.1. Tablet

        14.5.2. Solution

        14.5.3. Others

    14.6. Market Value Forecast, by Distribution Channel, 2017–2031

        14.6.1. Hospital Pharmacies

        14.6.2. Retail Pharmacies

        14.6.3. Online Pharmacies

    14.7. Market Value Forecast, by Country/Sub-region, 2017–2031

        14.7.1. China

        14.7.2. Japan

        14.7.3. India

        14.7.4. Australia & New Zealand

        14.7.5. Rest of Asia Pacific

    14.8. Market Attractiveness Analysis

        14.8.1. By Drug Type

        14.8.2. By Application

        14.8.3. By Route of Administration

        14.8.4. By Dosage Form

        14.8.5. By Distribution Channel

        14.8.6. By Country/Sub-region

15. Latin America Cardiotonic Agents Market Analysis and Forecast

    15.1. Introduction

        15.1.1. Key Findings

    15.2. Market Value Forecast, by Drug Type, 2017–2031

        15.2.1. Digitalis Glycosides

        15.2.2. Phosphodiesterase Inhibitors

        15.2.3. Cardioprotectants

        15.2.4. Sympathomimetic Agents

        15.2.5. Others

    15.3. Market Value Forecast, by Application, 2017–2031

        15.3.1. Cardiac Surgical Procedures

        15.3.2. Atrial Fibrillation

        15.3.3. Heart Failure

        15.3.4. Pulmonary Hypertension

        15.3.5. Others (Atrial Flutter, Cardiogenic Shock, etc.)

    15.4. Market Value Forecast, by Route of Administration, 2017–2031

        15.4.1. Oral

        15.4.2. Parenteral

    15.5. Market Value Forecast, by Dosage Form, 2017–2031

        15.5.1. Tablet

        15.5.2. Solution

        15.5.3. Others

    15.6. Market Value Forecast, by Distribution Channel, 2017–2031

        15.6.1. Hospital Pharmacies

        15.6.2. Retail Pharmacies

        15.6.3. Online Pharmacies

    15.7. Market Value Forecast, by Country/Sub-region, 2017–2031

        15.7.1. Brazil

        15.7.2. Mexico

        15.7.3. Rest of Latin America

    15.8. Market Attractiveness Analysis

        15.8.1. By Drug Type

        15.8.2. By Application

        15.8.3. By Route of Administration

        15.8.4. By Dosage Form

        15.8.5. By Distribution Channel

        15.8.6. By Country/Sub-region

16. Middle East & Africa Cardiotonic Agents Market Analysis and Forecast

    16.1. Introduction

        16.1.1. Key Findings

    16.2. Market Value Forecast, by Drug Type, 2017–2031

        16.2.1. Digitalis Glycosides

        16.2.2. Phosphodiesterase Inhibitors

        16.2.3. Cardioprotectants

        16.2.4. Sympathomimetic Agents

        16.2.5. Others

    16.3. Market Value Forecast, by Application, 2017–2031

        16.3.1. Cardiac Surgical Procedures

        16.3.2. Atrial Fibrillation

        16.3.3. Heart Failure

        16.3.4. Pulmonary Hypertension

        16.3.5. Others (Atrial Flutter, Cardiogenic Shock, etc.)

    16.4. Market Value Forecast, by Route of Administration, 2017–2031

        16.4.1. Oral

        16.4.2. Parenteral

    16.5. Market Value Forecast, by Dosage Form, 2017–2031

        16.5.1. Tablet

        16.5.2. Solution

        16.5.3. Others

    16.6. Market Value Forecast, by Distribution Channel, 2017–2031

        16.6.1. Hospital Pharmacies

        16.6.2. Retail Pharmacies

        16.6.3. Online Pharmacies

    16.7. Market Value Forecast, by Country/Sub-region, 2017–2031

        16.7.1. GCC Countries

        16.7.2. South Africa

        16.7.3. Rest of Middle East & Africa

    16.8. Market Attractiveness Analysis

        16.8.1. By Drug Type

        16.8.2. By Application

        16.8.3. By Route of Administration

        16.8.4. By Dosage Form

        16.8.5. By Distribution Channel

        16.8.6. By Country/Sub-region

17. Competition Landscape

    17.1. Market Player – Competition Matrix (By Tier and Size of Companies)

    17.2. Market Share Analysis, by Company (2022)

    17.3. Company Profiles

        17.3.1. Amneal Pharmaceuticals LLC

            17.3.1.1. Company Overview (HQ, Business Segments, Employee Strength)

            17.3.1.2. Product Portfolio

            17.3.1.3. Financial Overview

            17.3.1.4. SWOT Analysis

            17.3.1.5. Strategic Overview

        17.3.2. Pfizer Inc.

            17.3.2.1. Company Overview (HQ, Business Segments, Employee Strength)

            17.3.2.2. Product Portfolio

            17.3.2.3. Financial Overview

            17.3.2.4. SWOT Analysis

            17.3.2.5. Strategic Overview

        17.3.3. Hikma Pharmaceuticals PLC

            17.3.3.1. Company Overview (HQ, Business Segments, Employee Strength)

            17.3.3.2. Product Portfolio

            17.3.3.3. Financial Overview

            17.3.3.4. SWOT Analysis

            17.3.3.5. Strategic Overview

        17.3.4. Fresenius Kabi

            17.3.4.1. Company Overview (HQ, Business Segments, Employee Strength)

            17.3.4.2. Product Portfolio

            17.3.4.3. Financial Overview

            17.3.4.4. SWOT Analysis

            17.3.4.5. Strategic Overview

        17.3.5. Midas Pharma GmbH

            17.3.5.1. Company Overview (HQ, Business Segments, Employee Strength)

            17.3.5.2. Product Portfolio

            17.3.5.3. Financial Overview

            17.3.5.4. SWOT Analysis

            17.3.5.5. Strategic Overview

        17.3.6. Sanofi

            17.3.6.1. Company Overview (HQ, Business Segments, Employee Strength)

            17.3.6.2. Product Portfolio

            17.3.6.3. Financial Overview

            17.3.6.4. SWOT Analysis

            17.3.6.5. Strategic Overview

        17.3.7. Aurobindo Pharma Limited

            17.3.7.1. Company Overview (HQ, Business Segments, Employee Strength)

            17.3.7.2. Product Portfolio

            17.3.7.3. Financial Overview

            17.3.7.4. SWOT Analysis

            17.3.7.5. Strategic Overview

        17.3.8. SimSon Pharma Limited

            17.3.8.1. Company Overview (HQ, Business Segments, Employee Strength)

            17.3.8.2. Product Portfolio

            17.3.8.3. Financial Overview

            17.3.8.4. SWOT Analysis

            17.3.8.5. Strategic Overview

        17.3.9. Other Players

            17.3.9.1. Company Overview (HQ, Business Segments, Employee Strength)

            17.3.9.2. Product Portfolio

            17.3.9.3. Financial Overview

            17.3.9.4. SWOT Analysis

            17.3.9.5. Strategic Overview

List of Tables

Table 01: Global Cardiotonic Agents Market Value (US$ Mn) Forecast, by Drug Type, 2017–2031

Table 02: Global Cardiotonic Agents Market Value (US$ Mn) Forecast, by Application, 2017–2031

Table 03: Global Cardiotonic Agents Market Value (US$ Mn) Forecast, by Route of Administration, 2017–2031

Table 04: Global Cardiotonic Agents Market Value (US$ Mn) Forecast, by Dosage Form, 2017–2031

Table 05: Global Cardiotonic Agents Market Value (US$ Mn) Forecast, by Distribution Channel, 2017–2031

Table 06: Global Cardiotonic Agents Market Value (US$ Mn) Forecast, by Country/Region, 2017–2031

Table 07: North America Cardiotonic Agents Market Value (US$ Mn) Forecast, by Drug Type, 2017–2031

Table 08: North America Cardiotonic Agents Market Value (US$ Mn) Forecast, by Application, 2017–2031

Table 10: North America Cardiotonic Agents Market Value (US$ Mn) Forecast, by Route of Administration, 2017–2031

Table 11: North America Cardiotonic Agents Market Value (US$ Mn) Forecast, by Dosage Form, 2017–2031

Table 13: North America Cardiotonic Agents Market Value (US$ Mn) Forecast, by Distribution Channel, 2017–2031

Table 14: Europe Cardiotonic Agents Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017–2031

Table 15: Europe Cardiotonic Agents Market Value (US$ Mn) Forecast, by Drug Type, 2017–2031

Table 16: Europe Cardiotonic Agents Market Value (US$ Mn) Forecast, by Application, 2017–2031

Table 17: Europe Cardiotonic Agents Market Value (US$ Mn) Forecast, by Route of Administration, 2017–2031

Table 18: Europe Cardiotonic Agents Market Value (US$ Mn) Forecast, by Dosage Form, 2017–2031

Table 20: Europe Cardiotonic Agents Market Value (US$ Mn) Forecast, by Distribution Channel, 2017–2031

Table 21: Asia Pacific Cardiotonic Agents Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017–2031

Table 22: Asia Pacific Cardiotonic Agents Market Value (US$ Mn) Forecast, by Drug Type, 2017–2031

Table 23: Asia Pacific Cardiotonic Agents Market Value (US$ Mn) Forecast, by Application, 2017–2031

Table 24: Asia Pacific Cardiotonic Agents Market Value (US$ Mn) Forecast, by Route of Administration, 2017–2031

Table 25: Asia Pacific Cardiotonic Agents Market Value (US$ Mn) Forecast, by Dosage Form, 2017–2031

Table 26: Latin America Cardiotonic Agents Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017–2031

Table 27: Latin America Cardiotonic Agents Market Value (US$ Mn) Forecast, by Drug Type, 2017–2031

Table 28: Latin America Cardiotonic Agents Market Value (US$ Mn) Forecast, by Application, 2017–2031

Table 29: Latin America Cardiotonic Agents Market Value (US$ Mn) Forecast, by Route of Administration, 2017–2031

Table 30: Latin America Cardiotonic Agents Market Value (US$ Mn) Forecast, by Dosage Form, 2017–2031

Table 31: Middle East & Africa Cardiotonic Agents Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017–2031

Table 32: Middle East & Africa Cardiotonic Agents Market Value (US$ Mn) Forecast, by Drug Type, 2017–2031

Table 33: Middle East & Africa Cardiotonic Agents Market Value (US$ Mn) Forecast, by Application, 2017–2031

Table 34: Middle East & Africa Cardiotonic Agents Market Value (US$ Mn) Forecast, by Route of Administration, 2017–2031

Table 35: Middle East & Africa Cardiotonic Agents Market Value (US$ Mn) Forecast, by Dosage Form, 2017–2031

List of Figures

Figure 01: Global Cardiotonic Agents Market Value (US$ Mn) Forecast, 2017–2031

Figure 02: Cardiotonic Agents Market Value Share, by Drug Type, 2022

Figure 03: Cardiotonic Agents Market Value Share, by Application, 2022

Figure 04: Cardiotonic Agents Market Value Share, by Route of Administration, 2022

Figure 05: Cardiotonic Agents Market Value Share, by Dosage Form, 2022

Figure 06: Cardiotonic Agents Market Value Share, by Distribution Channel, 2022

Figure 07: Cardiotonic Agents Market Value Share, by Radiotracer Type, 2022

Figure 08: Global Cardiotonic Agents Market Value Share Analysis, by Drug Type 2022 and 2031

Figure 09: Global Cardiotonic Agents Market Attractiveness Analysis, Drug Type, 2023–2031

Figure 10: Global Cardiotonic Agents Market Revenue (US$ Mn), by Digitalis Glycosides, 2017–2031

Figure 11: Global Cardiotonic Agents Market Revenue (US$ Mn), by Phosphodiesterase Inhibitors, 2017–2031

Figure 12: Global Cardiotonic Agents Market Revenue (US$ Mn), by Cardioprotectants, 2017–2031

Figure 13: Global Cardiotonic Agents Market Revenue (US$ Mn), by Sympathomimetic Agents, 2017–2031

Figure 14: Global Cardiotonic Agents Market Revenue (US$ Mn), by Others, 2017–2031

Figure 15: Global Cardiotonic Agents Market Value Share Analysis, by Application 2022 and 2031

Figure 16: Global Cardiotonic Agents Market Attractiveness Analysis, Application, 2023–2031

Figure 17: Global Cardiotonic Agents Market Revenue (US$ Mn), by Cardiac Surgical Procedures, 2017–2031

Figure 18: Global Cardiotonic Agents Market Revenue (US$ Mn), by Atrial Fibrillation, 2017–2031

Figure 19: Global Cardiotonic Agents Market Revenue (US$ Mn), by Heart Failure, 2017–2031

Figure 20: Global Cardiotonic Agents Market Revenue (US$ Mn), by Pulmonary Hypertension, 2017–2031

Figure 21: Global Cardiotonic Agents Market Revenue (US$ Mn), by Others (Atrial Flutter, Cardiogenic Shock, etc.), 2017–2031

Figure 21: Global Cardiotonic Agents Market Value Share Analysis, by Route of Administration 2022 and 2031

Figure 23: Global Cardiotonic Agents Market Attractiveness Analysis, Route of Administration, 2023–2031

Figure 24: Global Cardiotonic Agents Market Revenue (US$ Mn), by Oral, 2017–2031

Figure 25: Global Cardiotonic Agents Market Revenue (US$ Mn), by Parenteral, 2017–2031

Figure 26: Global Cardiotonic Agents Market Value Share Analysis, by Dosage Form 2022 and 2031

Figure 27: Global Cardiotonic Agents Market Attractiveness Analysis, Dosage Form, 2023–2031

Figure 28: Global Cardiotonic Agents Market Revenue (US$ Mn), by Tablet, 2017–2031

Figure 29: Global Cardiotonic Agents Market Revenue (US$ Mn), by Solution, 2017–2031

Figure 30: Global Cardiotonic Agents Market Value Share Analysis, by Others 2022 and 2031

Figure 31: Global Cardiotonic Agents Market Value Share Analysis, by Distribution Channel 2022 and 2031

Figure 32: Global Cardiotonic Agents Market Attractiveness Analysis, Distribution Channel, 2023–2031

Figure 33: Global Cardiotonic Agents Market Revenue (US$ Mn), by Hospital Pharmacies, 2017–2031

Figure 34: Global Cardiotonic Agents Market Revenue (US$ Mn), by Retail Pharmacies, 2017–2031

Figure 35: Global Cardiotonic Agents Market Revenue (US$ Mn), by Online Pharmacies, 2017–2031

Figure 36: Global Cardiotonic Agents Market Value Share Analysis, by Country, 2022 and 2031

Figure 37: Global Cardiotonic Agents Market Attractiveness Analysis, by Country, 2023–2031

Figure 38: North America Cardiotonic Agents Market Value (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, 2017–2031

Figure 39: North America Cardiotonic Agents Market Value Share Analysis, by Drug Type 2022 and 2031

Figure 40: North America Cardiotonic Agents Market Attractiveness Analysis, Drug Type, 2023–2031

Figure 41: North America Cardiotonic Agents Market Value Share Analysis, by Application 2022 and 2031

Figure 42: North America Cardiotonic Agents Market Attractiveness Analysis, Application, 2023–2031

Figure 43: North America Cardiotonic Agents Market Value Share Analysis, by Route of Administration 2022 and 2031

Figure 44: North America Cardiotonic Agents Market Attractiveness Analysis, Route of Administration, 2023–2031

Figure 45: North America Cardiotonic Agents Market Value Share Analysis, by Dosage Form 2022 and 2031

Figure 46: North America Cardiotonic Agents Market Attractiveness Analysis, Dosage Form, 2023–2031

Figure 47: North America Cardiotonic Agents Market Value Share Analysis, by Distribution Channel 2022 and 2031

Figure 48: North America Cardiotonic Agents Market Attractiveness Analysis, Distribution Channel, 2023–2031

Figure 49: Europe Cardiotonic Agents Market Value (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, 2017–2031

Figure 50: Europe Cardiotonic Agents Market Value Share Analysis, by Country/Sub-region, 2022 and 2031

Figure 51: Europe Cardiotonic Agents Market Attractiveness Analysis, by Country/Sub-region, 2023–2031

Figure 52: Europe Cardiotonic Agents Market Value Share Analysis, by Drug Type 2022 and 2031

Figure 53: Europe Cardiotonic Agents Market Attractiveness Analysis, Drug Type, 2023–2031

Figure 54: Europe Cardiotonic Agents Market Value Share Analysis, by Application, 2022 and 2031

Figure 55: Europe Cardiotonic Agents Market Attractiveness Analysis, Application, 2023–2031

Figure 56: Europe Cardiotonic Agents Market Value Share Analysis, by Route of Administration 2022 and 2031

Figure 57: Europe Cardiotonic Agents Market Attractiveness Analysis, Route of Administration, 2023–2031

Figure 58: Europe Cardiotonic Agents Market Value Share Analysis, by Dosage Form 2022 and 2031

Figure 59: Europe Cardiotonic Agents Market Attractiveness Analysis, Dosage Form, 2023–2031

Figure 60: Europe Cardiotonic Agents Market Value Share Analysis, by Distribution Channel, 2022 and 2031

Figure 61: Europe Cardiotonic Agents Market Attractiveness Analysis, Distribution Channel, 2023–2031

Figure 62: Asia Pacific Cardiotonic Agents Market Value (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, 2017–2031

Figure 63: Asia Pacific Cardiotonic Agents Market Value Share Analysis, by Country/Sub-region, 2022 and 2031

Figure 64: Asia Pacific Cardiotonic Agents Market Attractiveness Analysis, by Country/Sub-region, 2023–2031

Figure 65: Asia Pacific Cardiotonic Agents Market Value Share Analysis, by Drug Type 2022 and 2031

Figure 66: Asia Pacific Cardiotonic Agents Market Attractiveness Analysis, Drug Type, 2023–2031

Figure 67: Asia Pacific Cardiotonic Agents Market Value Share Analysis, by Application, 2022 and 2031

Figure 68: Asia Pacific Cardiotonic Agents Market Attractiveness Analysis, Application, 2023–2031

Figure 69: Asia Pacific Cardiotonic Agents Market Value Share Analysis, by Route of Administration 2022 and 2031

Figure 70: Asia Pacific Cardiotonic Agents Market Attractiveness Analysis, Route of Administration, 2023–2031

Figure 71: Asia Pacific Cardiotonic Agents Market Value Share Analysis, by Dosage Form 2022 and 2031

Figure 72: Asia Pacific Cardiotonic Agents Market Attractiveness Analysis, Dosage Form, 2023–2031

Figure 73: Asia Pacific Cardiotonic Agents Market Value Share Analysis, by Distribution Channel, 2022 and 2031

Figure 74: Asia Pacific Cardiotonic Agents Market Attractiveness Analysis, Distribution Channel, 2023–2031

Figure 75: Latin America Cardiotonic Agents Market Value (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, 2017–2031

Figure 76: Latin America Cardiotonic Agents Market Value Share Analysis, by Country/Sub-region, 2022 and 2031

Figure 77: Latin America Cardiotonic Agents Market Attractiveness Analysis, by Country/Sub-region, 2023–2031

Figure 78: Latin America Cardiotonic Agents Market Value Share Analysis, by Drug Type 2022 and 2031

Figure 79: Latin America Cardiotonic Agents Market Attractiveness Analysis, Drug Type, 2023–2031

Figure 80: Latin America Cardiotonic Agents Market Value Share Analysis, by Application, 2022 and 2031

Figure 81: Latin America Cardiotonic Agents Market Attractiveness Analysis, Application, 2023–2031

Figure 82: Latin America Cardiotonic Agents Market Value Share Analysis, by Route of Administration 2022 and 2031

Figure 83: Latin America Cardiotonic Agents Market Attractiveness Analysis, Route of Administration, 2023–2031

Figure 84: Latin America Cardiotonic Agents Market Value Share Analysis, by Dosage Form 2022 and 2031

Figure 85: Latin America Cardiotonic Agents Market Attractiveness Analysis, Dosage Form, 2023–2031

Figure 86: Latin America Cardiotonic Agents Market Value Share Analysis, by Distribution Channel, 2022 and 2031

Figure 87: Latin America Cardiotonic Agents Market Attractiveness Analysis, Distribution Channel, 2023–2031

Figure 88: Middle East & Africa Cardiotonic Agents Market Value (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, 2017–2031

Figure 89: Middle East & Africa Cardiotonic Agents Market Value Share Analysis, by Country/Sub-region, 2022 and 2031

Figure 90: Middle East & Africa Cardiotonic Agents Market Attractiveness Analysis, by Country/Sub-region, 2023–2031

Figure 91: Middle East & Africa Cardiotonic Agents Market Value Share Analysis, by Drug Type 2022 and 2031

Figure 92: Middle East & Africa Cardiotonic Agents Market Attractiveness Analysis, Drug Type, 2023–2031

Figure 93: Middle East & Africa Cardiotonic Agents Market Value Share Analysis, by Application, 2022 and 2031

Figure 94: Middle East & Africa Cardiotonic Agents Market Attractiveness Analysis, Application, 2023–2031

Figure 95: Middle East & Africa Cardiotonic Agents Market Value Share Analysis, by Route of Administration 2022 and 2031

Figure 96: Middle East & Africa Cardiotonic Agents Market Attractiveness Analysis, Route of Administration, 2023–2031

Figure 97: Middle East & Africa Cardiotonic Agents Market Value Share Analysis, by Dosage Form 2022 and 2031

Figure 98: Middle East & Africa Cardiotonic Agents Market Attractiveness Analysis, Dosage Form, 2023–2031

Figure 99: Middle East & Africa Cardiotonic Agents Market Value Share Analysis, by Distribution Channel, 2022 and 2031

Figure 100: Middle East & Africa Cardiotonic Agents Market Attractiveness Analysis, Distribution Channel, 2023–2031

Copyright © Transparency Market Research, Inc. All Rights reserved